Journal of the American College of Cardiology最新文献

{"title":"Impact of Renal and Liver Function on Clinical Outcomes Following Tricuspid Valve Transcatheter Edge-to-Edge Repair.","authors":"Ulrich P Jorde, Raymond Benza, Patrick M McCarthy, Gorav Ailawadi, Brian Whisenant, Raj Makkar, Peter Tadros, Hursh Naik, Neil Fam, Andrew J Sauer, Sandhya Murthy, Saibal Kar, Ralph Stephan von Bardeleben, Rebecca T Hahn, Nadira Hamid, Jacob Zbinden, Paul Sorajja, David Adams","doi":"10.1016/j.jacc.2024.08.044","DOIUrl":"10.1016/j.jacc.2024.08.044","url":null,"abstract":"<p><strong>Background: </strong>The TRILUMINATE Pivotal trial is a prospective, randomized, controlled study of patients with severe tricuspid regurgitation (TR). Venous congestion due to TR may lead to end-organ dysfunction and failure. The potential to reverse or stop further deterioration in end-organ function is an important goal of treatment.</p><p><strong>Objectives: </strong>This study sought to examine changes in end-organ function after tricuspid transcatheter edge-to-edge repair (TEER) and assess the association of baseline end-organ function with heart failure (HF) hospitalizations and mortality.</p><p><strong>Methods: </strong>Subjects were randomized 1:1 to either the TEER group (TriClip System + medical therapy) or control group (medical therapy alone). Laboratory assessments and TR grading were performed at baseline and at all follow-up visits (discharge, 30 days, 6 months, and 12 months). An independent echocardiography core laboratory assessed TR severity and an independent clinical events committee adjudicated adverse events.</p><p><strong>Results: </strong>A total of 572 subjects were enrolled and randomized (285 TEER, 287 control patients). Patients with moderate-to-severe end-organ impairment (estimated glomerular ejection fraction [eGFR] <45 mL/min/1.73 m² or Model for End-Stage Liver Disease excluding INR [MELD-XI] >15) at baseline had increased incidence of HF hospitalization and death through 12 months, regardless of treatment. There were no statistically significant differences between TEER and control patients in eGFR or MELD-XI at 12 months. In subgroup analyses examining only successful TEER patients (moderate or less TR at discharge) compared with control patients, as well as when censoring patients with normal baseline values, both eGFR (+3.55 ± 1.04 mL/min/1.73 m² vs 0.07 ± 1.10 mL/min/1.73 m²; P = 0.022) and MELD-XI (-0.52 ± 0.18 vs 0.34 ± 0.18; P = 0.0007) improved.</p><p><strong>Conclusions: </strong>Baseline end-organ function was associated with HF hospitalization and death in patients with severe TR. At 12 months, eGFR and MELD-XI scores were not statistically significantly different between the overall TEER and control groups. In patients who had successful TEER, statistically significant, yet small, favorable changes occurred for both eGFR and MELD-XI. Further investigation is needed to assess whether these changes in end-organ function after successful TEER are clinically meaningful and reduce HF hospitalization or death. (Clinical Trial to Evaluate Cardiovascular Outcomes In Patients Treated With the Tricuspid Valve Repair System Pivotal [TRILUMINATE Pivotal]; NCT03904147).</p>","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":" ","pages":"2446-2456"},"PeriodicalIF":21.7,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142120141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Excess Mortality and Hospitalizations Associated With Seasonal Influenza in Patients With Heart Failure.","authors":"Daniel Modin, Brian Claggett, Niklas Dyrby Johansen, Scott D Solomon, Ramona Trebbien, Thyra Grove Krause, Jens-Ulrik Stæhr Jensen, Mikkel Porsborg Andersen, Gunnar Gislason, Tor Biering-Sørensen","doi":"10.1016/j.jacc.2024.08.048","DOIUrl":"10.1016/j.jacc.2024.08.048","url":null,"abstract":"<p><strong>Background: </strong>Influenza virus may cause severe infection in patients with heart failure. It is known that influenza infection is associated with increased morbidity and mortality in patients with heart failure. However, less is known about the excess burden of morbidity and mortality caused by influenza infection in patients with heart failure at a population level.</p><p><strong>Objectives: </strong>The purpose of this study was to estimate the excess burden of morbidity and mortality as determined by annual excess number of deaths and hospitalizations associated with influenza infection in patients with heart failure in Denmark.</p><p><strong>Methods: </strong>We collected nationwide data on weekly number of deaths and hospitalizations among patients with heart failure in Denmark and weekly estimates of influenza circulation as determined by the proportion of positive influenza samples analyzed at all Danish Hospitals. These data were correlated in a time series linear regression model, and this model was used to estimate the annual excess number of deaths and hospitalizations attributable to influenza circulation among patients with heart failure in Denmark. The model also included data on weekly mean temperature and restricted cubic spline terms to account for seasonality and trends over time.</p><p><strong>Results: </strong>Data were available from 2010 to 2018 encompassing 8 influenza seasons with an annual mean of 25,180 samples tested for influenza at Danish hospitals. Among an annual mean of 70,570 patients with heart failure, our model estimated that influenza activity was associated with an annual excess of 250 all-cause deaths (95% CI: 144-489 deaths) corresponding to 2.6% of all all-cause deaths (95% CI: 1.5%-5.1%) in patients with heart failure. Similarly, influenza activity was associated with an annual excess of 115 cardiovascular deaths (95% CI: 62-244 deaths) corresponding to 2.9% of all cardiovascular deaths (95% CI: 1.5%-6.1%). Influenza activity was also associated with an annual excess of 251 hospitalizations for pneumonia or influenza (95% CI: 107-533 hospitalizations) corresponding to 5.0% of all hospitalizations for pneumonia or influenza.</p><p><strong>Conclusions: </strong>Our results indicate that influenza activity likely causes substantial morbidity and mortality among patients with heart failure. Notably, our study suggests that approximately 2.6% of all deaths and 5.0% of all hospitalizations with influenza or pneumonia may be attributed to influenza in patients with heart failure.</p>","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":" ","pages":"2460-2467"},"PeriodicalIF":21.7,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142120140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2024 ACC Expert Consensus Decision Pathway on Practical Approaches for Arrhythmia Monitoring After Stroke: A Report of the American College of Cardiology Solution Set Oversight Committee","authors":"Michael T. Spooner, Steven R. Messé, Seemant Chaturvedi, Monika M. Do, Ty J. Gluckman, Janet K. Han, Andrea M. Russo, Sherry J. Saxonhouse, Newton B. Wiggins","doi":"10.1016/j.jacc.2024.10.100","DOIUrl":"https://doi.org/10.1016/j.jacc.2024.10.100","url":null,"abstract":"&lt;h2&gt;Section snippets&lt;/h2&gt;&lt;section&gt;&lt;section&gt;&lt;h2&gt;Solution Set Oversight Committee&lt;/h2&gt;Nicole M. Bhave, MD, FACC, &lt;em&gt;Chair&lt;/em&gt;Niti R. Aggarwal, MD, FACCKatie Bates, ARNP, DNPJohn P. Erwin &lt;span&gt;III&lt;/span&gt;, MD, FACCMartha Gulati, MD, MS, FACCDharam J. Kumbhani, MD, SM, FACCGurusher S. Panjrath, MBBS, FACCBarbara Wiggins, PharmD, FACCMegan Coylewright, MD, MPH, FACC, &lt;em&gt;Ex Officio&lt;/em&gt;&lt;/section&gt;&lt;/section&gt;&lt;section&gt;&lt;section&gt;&lt;h2&gt;Table of Contents&lt;/h2&gt;&lt;ul&gt;&lt;li&gt;&lt;span&gt;1.&lt;/span&gt;&lt;span&gt;Introduction&lt;!-- --&gt; &lt;!-- --&gt;2&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;2.&lt;/span&gt;&lt;span&gt;Assumptions and Definitions&lt;!-- --&gt; &lt;!-- --&gt;3&lt;ul&gt;&lt;li&gt;&lt;span&gt;2.1.&lt;/span&gt;&lt;span&gt;General Clinical Assumptions&lt;!-- --&gt; &lt;!-- --&gt;3&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;2.2.&lt;/span&gt;&lt;span&gt;Definitions&lt;!-- --&gt; &lt;!-- --&gt;3&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;3.&lt;/span&gt;&lt;span&gt;Pathway Summary Graphic&lt;!-- --&gt; &lt;!-- --&gt;4&lt;ul&gt;&lt;li&gt;&lt;span&gt;&lt;/span&gt;&lt;span&gt;Figure 1. Pathway Summary Graphic&lt;!-- --&gt; &lt;!-- --&gt;4&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;4.&lt;/span&gt;&lt;span&gt;Description, Rationale, and Implication of Pathway&lt;!-- --&gt; &lt;!-- --&gt;4&lt;ul&gt;&lt;li&gt;&lt;span&gt;4.1.&lt;/span&gt;&lt;span&gt;Adults With Stroke of Presumed Cardiac Origin Who Require Anticoagulation&lt;!-- --&gt; &lt;!-- --&gt;4&lt;ul&gt;&lt;li&gt;&lt;span&gt;4.1.1.&lt;/span&gt;&lt;span&gt;Role for Monitoring&lt;!-- --&gt; &lt;!-- --&gt;4&lt;ul&gt;&lt;li&gt;&lt;span&gt;&lt;/span&gt;&lt;span&gt;Figure 2. Flowchart of Poststroke Monitoring and Treatment Strategy&lt;!-- --&gt; &lt;!-- --&gt;5&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;4.2.&lt;/span&gt;&lt;span&gt;Adults With Ischemic Stroke From Presumed Small- or Large-Vessel Disease&lt;!-- --&gt; &lt;!-- --&gt;5&lt;ul&gt;&lt;li&gt;&lt;span&gt;4.2.1.&lt;/span&gt;&lt;span&gt;Role for Monitoring&lt;!-- --&gt; &lt;!-- --&gt;7&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;4.3.&lt;/span&gt;&lt;span&gt;Adults With Ischemic Stroke and Unclear Source&lt;!-- --&gt; &lt;!-- --&gt;8&lt;ul&gt;&lt;li&gt;&lt;span&gt;4.3.1.&lt;/span&gt;&lt;span&gt;Role&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/section&gt;&lt;/section&gt;&lt;section&gt;&lt;section&gt;&lt;h2&gt;Assumptions and Definitions&lt;/h2&gt;To facilitate interpretation of the recommendations provided in this ECDP, specific assumptions were made by the writing committee, as specified.&lt;/section&gt;&lt;/section&gt;&lt;section&gt;&lt;section&gt;&lt;h2&gt;Pathway Summary Graphic&lt;/h2&gt;Arrhythmia monitoring after a stroke requires three important steps (Figure 1). The first is a multidisciplinary evaluation to identify any potential mechanisms for the stroke. Ultimately, the stroke may be determined to be cryptogenic. The second step is risk assessment to determine the likelihood that a cardiac arrhythmia played a role in the stroke or may play a role in future stroke or nonstroke morbidity. The final step is choosing the optimal monitoring strategy for the patient that&lt;/section&gt;&lt;/section&gt;&lt;section&gt;&lt;section&gt;&lt;section&gt;&lt;h2&gt;Adults With Stroke of Presumed Cardiac Origin Who Require Anticoagulation&lt;/h2&gt;Many patients with an ischemic stroke of presumed cardiac origin require anticoagulation to reduce the risk of future events. Conditions that warrant consideration for long-term anticoagulation include AF, left atrial or left ventricular thrombus, postablation electrical isolation of the left atrial appendage, r","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":"49 1","pages":""},"PeriodicalIF":24.0,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142841062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Screening for Abdominal Aortic Aneurysms Still Prevents Ruptures: A Secondary Analysis of the VIVA Trial.","authors":"Marie Dahl, Mads Liisberg, Margrete Stenehjem, Islam Al Obeidi, Jes Sanddal Lindholt","doi":"10.1016/j.jacc.2024.09.011","DOIUrl":"10.1016/j.jacc.2024.09.011","url":null,"abstract":"","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":" ","pages":"2494-2496"},"PeriodicalIF":21.7,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142583309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Efficacy and Safety of Inclisiran: A Single-Country, Multicenter, Observational Study (CHOLINET Registry)","authors":"Paola Gargiulo, Federica Marzano, Mario Crisci, Rossella Marcucci, Dario Bruzzese, Alessandro Maloberti, Filippo Maria Sarullo, Gennaro Galasso, Ciro Indolfi, Giuseppe Musumeci, Antonella Corleto, Paolo Calabrò, Stefano Carugo, Gavino Casu, Amedeo Picciolo, Marco Matteo Ciccone, Claudio Bilato, Alberto Polimeni, Francesco Giallauria, Angelo Catalano, Pasquale Perrone Filardi","doi":"10.1016/j.jacc.2024.10.106","DOIUrl":"https://doi.org/10.1016/j.jacc.2024.10.106","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Methods</h2>CHOLINET is a single-country, multicenter, observational, prospective, phase 4 registry of Italian patients initiating inclisiran as part of clinical management. Reimbursement criteria (Italian Medicines Agency [AIFA], GU 231-03.10.2022) include patients at very high cardiovascular (CV) risk with LDL-C of ≥70 mg/dL on statin ± ezetimibe. Lipids were assessed at median of 17 days before each inclisiran administration. CV risk categorization was performed according to the European Society of</section></section><section><section><h2>Results</h2>A total of 659 patients were enrolled across 31 Italian sites between November 2022 and February 2024. Of these, 529 patients reached the 3-month milestone, and 513 patients (97%) received their second dose and had lipid levels measured. Additionally, of the 178 patients who reached the 9-month milestone, 171 (96%) received the third dose and had their lipid levels measured. The mean age was 63 years, and the majority were male (69%). Inclisiran was mostly prescribed by cardiologists (98%) and</section></section><section><section><h2>Discussion</h2>In this study, a reduction in LDL-C levels was observed in patients receiving inclisiran, with most of them achieving the LDL-C target without significant side effects at 3 and 9 months.Our data confirm the efficacy observed in randomized studies, reporting an LDL-C reduction of 50% to 55%¹ at day 90 and of 57% to 60.2%⁷^,⁸ at 9 months, consistent with our findings showing a 51.2% LDL-C reduction at 3 months and 55.7% at 9 months.Recently, VICTORION-INITIATE⁴ reported an LDL-C reduction of 57.7%</section></section><section><section><h2>Funding Support and Author Disclosures</h2>Dr Corsini has received consulting fees and lecture fees from Algorithm, Amarin, Amgen, DOC, Fidia, Novartis, Merck Sharp &amp; Dohme, Recordati Spa, Sanofi, Servier, and Viatris; and has received grant support from Daiichi-Sankyo. The other authors have reported that they have no relationships relevant to the contents of this paper to disclose.</section></section><section><section><h2>Acknowledgments</h2>The CHOLINET Investigators include Luca Gallo, MD, Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy; Ermanno Nardi, MD, Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy; Antonio Luca Maria Parlati, Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy; Lucia Barbieri, MD, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, and</section></section>","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":"23 1","pages":""},"PeriodicalIF":24.0,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142804791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Giving Cardiovascular Clinicians a Voice in Evidence Generation: A Collaboration Between FDA and JACC","authors":"Haider J. Warraich, Harlan M. Krumholz, Robert M. Califf","doi":"10.1016/j.jacc.2024.11.022","DOIUrl":"https://doi.org/10.1016/j.jacc.2024.11.022","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Funding Support and Author Disclosures</h2>Dr Warraich has served on the medical advisory board for GoodRx. Dr Krumholz is the Editor-in-Chief of <em>JACC</em>; has received stock options for advisory roles from Element Science and Identifeye; has received payments for advisory roles from F-Prime; is a cofounder of and holds equity in Hugo Health, Refactor Health, and ENSIGHT-AI; and is associated with research contracts through Yale University from Janssen, Kenvue, Novartis, and Pfizer. Dr Califf has been an employee of and held equity in</section></section>","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":"28 1","pages":""},"PeriodicalIF":24.0,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142804782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rheumatic Valve Surgery in Sudan: Results in 7,449 Patients at the Salam Centre for Cardiac Surgery","authors":"Gina Portella, Liliane Chatenoud, Sofia Gatti, Alessandro C. Salvati, Lino Asta, Salvatore Lentini, Juha Puntila, Franco Masini, Sofia Redaelli, Alessandro Mocini, Suha Abdelwahab Abdallah, Sohayda Hussein Abdalla Abdalla, Nicoletta Erba, Elena Giovanella, Dimiana Raafat Shafig Saber, Daniela Rocchi, Manahel Badr Saad, Lorenzo Valgoi, Paolo Malerba, Luca Rolla, Martin Langer","doi":"10.1016/j.jacc.2024.09.1232","DOIUrl":"https://doi.org/10.1016/j.jacc.2024.09.1232","url":null,"abstract":"<h2>Section snippets</h2><section><section><section><h2>Study design and setting</h2>This retrospective cohort includes all patients admitted for RHD surgery at the Salam Centre from April 2007 to December 2021, with follow-up of patients discharged alive evaluated up to July 2022. The Salam Centre⁷ admits about 80% of patients from Sudan and 20% from neighboring countries, as per agreement with the government. The hospital was built and is managed by the NGO, EMERGENCY, which supplies equipment, prosthetic valves, drugs, technical support, national and international staffing,</section></section></section><section><section><h2>Results</h2>From 2007 to 2021, 7,449 patients with RHD underwent single (N = 3,879: mitral valve [MV], n = 3,043; aortic valve [AV], n = 829; tricuspid valve [TV], n = 7), double (N = 2,856: MV + AV, n = 1,472; MV + TV, n = 1,380; TV + AV, n = 4), or triple (N = 714 MV + AV + TV) valve surgeries, of 9,506 open-heart procedures at the Salam Centre. Principal characteristics and patient outcomes are reported in Table 1. The mean age of patients was 25 years, with 20% &lt;15 years of age, and a mean body mass</section></section><section><section><h2>Discussion</h2>The Salam Centre experience summarizes outcomes for early- and late-surgical mortality for 7,449 patients undergoing valvular surgery for RHD. This is the largest cohort of RHD surgical patients in SSA and our findings extend the knowledge of pathophysiology and surgical management of rheumatic valvular disease in SSA. Although delivering care to a small percentage of affected patients, the Salam experience offers a model demonstrating feasibility, affordability, high-volume activity, and</section></section><section><section><h2>Funding Support and Author Disclosures</h2>The authors have reported that they have no relationships relevant to the contents of this paper to disclose.</section></section><section><section><h2>Acknowledgments</h2>The authors’ work is dedicated to our patients who are displaced because of the ongoing conflict and may have interrupted treatments. This project was supported by too many institutions, friends, supporters, and donors to mention all of them! Our founder, Gino Strada, has been chief surgeon for many years; his enthusiasm and expertise remain our cornerstone. The deidentified data of patients that underlie the results reported in this paper (text, tables, figures, and supplemental material) and</section></section>","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":"41 1","pages":""},"PeriodicalIF":24.0,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142804788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidental and Progressive Tobacco Smoking in Childhood and Subsequent Risk of Premature Cardiac Damage","authors":"Andrew O. Agbaje","doi":"10.1016/j.jacc.2024.09.1229","DOIUrl":"https://doi.org/10.1016/j.jacc.2024.09.1229","url":null,"abstract":"&lt;h2&gt;Section snippets&lt;/h2&gt;&lt;section&gt;&lt;section&gt;&lt;h2&gt;Methods&lt;/h2&gt;The ALSPAC birth cohort investigates factors that influence childhood development and growth.&lt;sup&gt;5&lt;/sup&gt; Of the original cohort of 14,901 children enrolled in the ALSPAC, 4,026 (27%) attended the clinic visit at 24 years of age. Of these, 1,958 (49%) had echocardiograms performed. The current analysis included 1,931 young adults with complete smoking and echocardiographic measures at age 24 years, of whom 890 had echocardiograms at both the 17- and 24-year visits. Ethical approval for the study was&lt;/section&gt;&lt;/section&gt;&lt;section&gt;&lt;section&gt;&lt;section&gt;&lt;h2&gt;Cohort Study Characteristics&lt;/h2&gt;Among 1,931 children (mean age 10.6 ± 0.26 years; 1,211 [62.7%] female]), the prevalence of smoking was 0.3%, 1.6%, 13.6%, 24%, and 26.4% at ages 10, 13, 15, 17, and 24 years, respectively. Sixty percent of children and adolescents who initiated tobacco smoking at ages 10, 13, 15, or 17 years continued smoking at age 24 years. The prevalence of LV hypertrophy increased from 2.8% at age 17 years to 7.5% at age 24 years while LVD dysfunction prevalence increased from 10.4% to 16.9%. Persistent&lt;/section&gt;&lt;/section&gt;&lt;/section&gt;&lt;section&gt;&lt;section&gt;&lt;h2&gt;Discussion&lt;/h2&gt;In a large population of apparently healthy children prospectively observed for 14 years from age 10 years through 24 years, persistent smoking from childhood was associated with the odds of premature cardiac functional and structural injury. Cigarette smoke has been associated with endothelial dysfunction and inflammation-induced atherosclerotic processes, abnormal lipid metabolism, increased myocardial hypoxia and oxygen demand, decreased cerebral oxygen availability, and altered metal&lt;/section&gt;&lt;/section&gt;&lt;section&gt;&lt;section&gt;&lt;h2&gt;Conclusions&lt;/h2&gt;Tobacco smoking from childhood through young adulthood was prospectively associated with 33% to 52% odds of premature structural and functional cardiac injury. Cigarette smoking from childhood was associated with cardiac mass increase, and one-third of the effect estimate was retained after controlling for competing risk factors.&lt;/section&gt;&lt;/section&gt;&lt;section&gt;&lt;section&gt;&lt;h2&gt;Funding Support and Author Disclosures&lt;/h2&gt;The UK Medical Research Council and Wellcome (grant reference number 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. The British Heart Foundation grant (CS/15/6/31468) funded blood pressure and Actigraph activity monitoring device measurement at 24 years. The Medical Research Council grant (MR/M006727/1) supported smoking data collection. A comprehensive list of grant funding is available on the ALSPAC website. Dr Agbaje's research group (UndeRstanding FITness and&lt;/section&gt;&lt;/section&gt;&lt;section&gt;&lt;section&gt;&lt;h2&gt;Acknowledgments&lt;/h2&gt;The author is extremely grateful to all the families who took part in this study, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, vo","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":"144 1","pages":""},"PeriodicalIF":24.0,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142804790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In CASTLE-HTx Trial We Trust","authors":"Christian Sohns, Nassir F. Marrouche, Harry J.G.M. Crijns, Samuel Sossalla, Vanessa Sciacca, Jan G.P. Tijssen, Philipp Sommer","doi":"10.1016/j.jacc.2024.10.092","DOIUrl":"https://doi.org/10.1016/j.jacc.2024.10.092","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Funding Support and Author Disclosures</h2>Dr Sohns has received research support and lecture fees from Medtronic, Abbott, Boston Scientific, and Biosense Webster; has served as a consultant for Medtronic, Boston Scientific, and Biosense Webster; and has received grant support from the Else Kröner-Fresenius-Stiftung and Deutsche Herzstiftung. Dr Marrouche has received grant support and consulting fees from Abbott, Wavelet Health, Medtronic, Vytronus, Biosense Webster, Boston Scientific, GE Health Care, and Siemens; has received</section></section>","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":"19 1","pages":""},"PeriodicalIF":24.0,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142804789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transcatheter Aortic Valve Replacement in Heart Failure, Reduced Ejection Fraction, and Moderate Aortic Stenosis","authors":"Patrick T. O’Gara","doi":"10.1016/j.jacc.2024.10.112","DOIUrl":"https://doi.org/10.1016/j.jacc.2024.10.112","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Funding Support and Author Disclosures</h2>The author has reported that he has no relationships relevant to the contents of this paper to disclose.</section></section>","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":"82 1","pages":""},"PeriodicalIF":24.0,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142804781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}